Insulin sensitizers such as metformin are of increasing interest in the management of PCOS, though they do not replace the need for behavioral interventions to achieve weight loss.
The recognition that insulin resistance has a central role in polycystic ovary syndrome has led to new approaches to treatment. While clinical presentations may still be managed symptomatically, there is increasing interest in insulin sensitisers including metformin. Drug treatments do not displace the management of behavioural risk factors to achieve weight loss in women who are overweight or obese. Weight loss leads to improvement in symptoms, and other long-term health benefits.
No takes yet. Share an insight, caveat, or question.
Beres Joyner (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: